

Efficacy of Metronidazole & Diloxanide Furoate in Amoebiasis and Giardiasis

MY KAZI MT BHATTI H I KHAN T MAHMAD

Department of Pediatric Medicine, King Edward Medical College Lahore

Correspondence to Dr. Mohammad Yaqoob Kazi, Associate Professor

This study was done to evaluate the efficacy of metronidazole & diloxanide combination in amoebic/giardiasis. It was an open prospective study on cases of diarrhea / dysentery. The children included were between the ages of 2 and 10 years. This cohort included 300 cases presenting with diarrhea / dysentery. The infected cases were selected on the basis of positive stool examination. There were 30 cases of amoebiasis, 14 of giardiasis and 6 of mixed infection. The presenting features of the cases of amoebiasis included dysentery (87%), diarrhoea (13%), abdominal pain (97%), vomiting (40%) and fever (30%) whereas those of giardiasis included diarrhoea (79%), abdominal pain (93%), and fever (7%). These children were prescribed a combination of metronidazole and diloxanide in therapeutic doses for five days. 92% parasitological cure of giardiasis and 98% of amoebiasis was observed after five days of treatment. Clinical cure rate in both cases was 98%. This combination is well tolerated and is logical, for cure of amoebiasis and giardiasis.

Key words : Metronidazole, Diloxanide, Amoebiasis, Giardiasis.

Amebiasis and giardiasis are parasitic diseases which have world-wide distribution. Their prevalence is more in the tropical areas of under developed countries like Pakistan. 500 million people carry *Entamoeba histolytica* (the causative organism of amoebiasis) in the world^{1,2}. And 50 million develop invasive amoebiasis². Similarly giardiasis is also one of the commonest pathogenic intestinal protozoal infections world-wide³. *E. histolytica* was first discovered by Lamble in 1859⁴ whereas *Giardia lamblia* (the causative organism of giardiasis) was originally identified by Leuwenhoek in 1600s but was also first recognized by Lamble as the etiological agent of dysentery⁵.

Various drugs have been used for the treatment of these parasitic diseases. Metronidazole which was discovered in 1959 was a major breakthrough in the treatment of protozoal diseases⁶. After its use problems were associated with use of metronidazole that included short duration of action, repeated dosage requirement and possible drug resistance, which prompted scientists to look for other drugs⁷. As a result diloxanide furoate was discovered. A combination of diloxanide furoate and metronidazole was subsequently used for treatment of amoebiasis and giardiasis⁸. Metronidazole works both in the lumen and the tissues whereas diloxanide furoate is a luminal drug⁹.

Aims and objectives

The aims of this study were to determine the frequency of amoebiasis and giardiasis in children presenting with acute diarrhea/dysenteric and to evaluate the efficacy of combination of metronidazole and diloxanide furoate.

Patients and methods

This will be an open prospective study to be conducted in the Department of Pediatrics, King Edward Medical College & Mayo Hospital, Lahore over a period of 6 months from June to November 2002. A total of 300 children from age 2 to 10 years of either sex presenting with diarrhea and dysentery associated with constitutional symptoms will be enrolled. Fresh samples of stool treated with 0.85% saline/iodine will be taken on day 0. These samples will be examined under low and high power objectives. Only those children (50 out of 300) found to be positive for *E. histolytica* and/or *G. lamblia* (cyst/vegetative) will be included in the study for further follow-up and analysis. Cases will be excluded from the study even if stool positive but there was history of anti amoebic/giardia drug intake recent past or those having severe/advanced systemic diseases like meningitis and sepsis etc. or if there is history of hypersensitivity to any drugs being used in the study. The children in the study group would be treated with combination of metronidazole of (30 mg/kg) and diloxanide furoate for a period of 5 days. Follow up will be done on day 3, 5 and 10, clinical examination and stool test to be repeated on each occasion. Outcome variables will be parasitological and clinical cure on days 3, 5 and 10.

Results

A total of 300 patients were enrolled for the study out of which 50 cases were selected on the basis of positive stool examination. These children were between ages of 2 and 10 years with the peak age of 4 years. Out of these 50 cases, 30 were positive for *E. histolytica*, 14 had giardiasis and

the rest 6 had mixed infection (Fig. 1). In amoebiasis group prominent features were abdominal pain (97%), dysentery (87%), vomiting (40%), fever (30%) and watery diarrhea (13%). In Giardiasis cases abdominal pain (93%), diarrhoea (79%) and fever (7%). In the mixed group the presenting features were dysenteric stools with recurrent abdominal pain. The male to female ratio showed almost equal distribution (26:24) (Fig. 2)

Figure 1: Sex distribution





Figure 2: Distribution of E histolytic and G lamblia.



Figure 3: Parasitological cure



The patients were treated with recommended doses of metronidazole/diloxanide and followed up as mentioned above. Clinical evaluation on day 5 and day 10 showed that all patients were symptom free except one patient with mixed infection group who was still passing blood on day 5. However he was also symptom-free at the end of the study. A total of 92% parasitological cure of giardiasis and 98% of amoebiasis was observed after five days of treatment. Clinical cure rate in both cases was over 98%. In this study no side effects were observed and the tolerability of the drug was excellent in all patients.

Table 1: Clinical cure rate

Symptoms	Day 3	Day 5	Day 10
Dysentery	96%	98%	100%
Diarrhea	38%	100%	100%
Tenesmus	75%	100%	100%
Pain abdomen	90%	100%	100%
Nausea	95%	100%	100%
Vomiting	96%	100%	100%

Table 2: Parasitological clearance.

	Day 0	Day 3	Day 5	Day 10
Amoebiasis	30	18	01	01
Giardiasis	14	4	01	01
Mixed	6	4	01	01

Discussion

Both amoebiasis and giardiasis are common childhood parasitic infections. These diseases are prevalent in countries like Pakistan where hygienic conditions are unsatisfactory¹⁰. We observed that 17% of children who presented with diarrhea or dysentery had amoebiasis or giardiasis or both. Other studies have shown that the frequency of amoebiasis is as high as 36% and giardiasis 44% in the general population in Karachi¹¹. World-wide prevalence rates of giardiasis vary from 4 – 42%¹².

In the present study statistical analysis of results show that metronidazole/diloxanide furoate combination is effective treatment for both amoebiasis and giardiasis. This is supported by parasitological and clinical cure rates of 92 – 98% and 98% respectively. Qureshi et al⁸ in a similar study from Pakistan have demonstrated a clinical response rate of 91% for amoebiasis, 84% of giardiasis and 100% parasitological response for both diseases. Clinical response rate in our study and the study conducted by Qureshi et al is better than the rates of 90% reported by many researchers from India^{9, 13, 14, 15} where socioeconomic conditions are similar to those in Pakistan.

The regimen with metronidazole/diloxanide furoate was very well tolerated by children and no side effects were observed. In the present study we conclude that every 5th child with diarrhoea or dysenteric symptoms in the age group of 2 – 12 years had parasitic infection. Metronidazole and diloxanide combination provided more than 98% parasitological and 100% clinical cure in 5 days treatment. Five days treatment is adequate for treatment of amoebiasis and giardiasis.

References

1. Ravdin JI. Entamoeba histolytica: From adherence to enteropathy. J Infect Dis 1989; 159: 420 – 429.
2. WHO. Prevention and control of intestinal parasitic infections. World Health Org Tech Report 1987; 749: 1 – 80.

3. Betani B, Patwari AK, Bajaj P, Diwan N, Anand VK. Recurrent abdominal pain in children. *Ind Pediatr* 2000; 37: 876 – 81.
4. Brandt H, Tamayo RP. Pathology of human amebiasis. *Hum Pathol* 1970; 1: 351 – 85.
5. Shultz MG. Giardiasis; *JAMA* 1975; 233(13): 13833 – 4.
6. Burchard GD, Mirelman D. *Entamoeba histolytica*: virulence potential and sensitivity to metronidazole and emetin of 4 isolates possessing non-pathogenic zymomers. *Exp Parasitol* 1988; 66: 231 – 42.
7. Willis AT. Secnidazole – a perspective. In: Katz N, Willis AT (eds) *Secnidazole – A new approach in 5 – Nitimidazole therapy*.
8. Qureshi H, Ali A, Baqi R, Ahmed W. Efficacy of a combined diloxanide furoate – metronidazole preparation in the treatment of amoebiasis and giardiasis. *J Intl Med Res* 1997; 25: 167 – 70.
9. Gaitonade BB, Koti ST, Pispati PK, et al. Evaluation of therapy in intestinal amoebiasis and parasitic diseases. *Ind Pract* 1979; 32: 583 – 48.
10. Tracy JW, Webster LT Jr. Drugs used in chemotherapy of protozoal infections. In Hardman JG, Lee E (eds) *Goodman and Gilman's The pharmacological basis of therapeutics*. 9th ed. New York. McGraw Hill; 1996: 987 – 1008.
11. Baqai R, Zuberi SJ. Prevalence of intestinal parasites in diarrhoeal patients. *J Pak Med Assoc* 1986; 36: 7 – 11.
12. LeChevallier MW, Norton WD, Lee RG. Occurrence of *Giardia* and *Cryptosporidium* spp in surface water supplies. *Appl Environ Microbiol* 1991; 57(9): 2610 -6.
13. Odongo DW. Entamizole therapy in intestinal amebiasis. *Ind Pract* 1979; 32: 556 – 9.
14. Habibullah CM, Padmanabham CG. Entamizole – a new antiamebic regimen in the treatment of intestinal amebiasis. *Ind Pract* 1979; 32: 570 6.
15. Antani J. Amoebiasis: a new therapeutic approach. *Ind Pract* 1979; 32 577 – 87.